Acorda podaje wyniki badań pierwszej próby klinicznej, przeciwciała rHIgM22. Może ono potencjalnie prowadzić do reminilizacji (odbudowy) uszkodzonych połączeń nerwowych.
“We’re encouraged by the outcome of this trial, which showed that rHIgM22 was well-tolerated at all of the dose levels we studied,” said Anthony Caggiano, M.D., Ph.D., Acorda’s Senior Vice President of Research and Development. “We are currently developing the protocol for our next Phase 1 clinical trial of rHIgM22. The data from this study will help inform the design of the next trial, which will enroll people with MS who are experiencing an active relapse.”
